Calidi Biotherapeutics, Inc./$CLDI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Ticker
$CLDI
Sector
Primary listing
AMEX
Employees
29
Headquarters
Website
CLDI Metrics
BasicAdvanced
$2.3m
-
-$5.95
1.42
-
Price and volume
Market cap
$2.3m
Beta
1.42
52-week high
$7.25
52-week low
$0.19
Average daily volume
6.8m
Financial strength
Current ratio
1.59
Quick ratio
1.423
Long term debt to equity
27.88
Total debt to equity
68.21
Interest coverage (TTM)
-65.93%
Profitability
EBITDA (TTM)
-18.589
Effective tax rate (TTM)
-0.07%
Management effectiveness
Return on assets (TTM)
-109.81%
Return on equity (TTM)
-700.65%
Valuation
Price to book
0.41
Price to tangible book (TTM)
0.41
Price to free cash flow (TTM)
-0.042
Free cash flow yield (TTM)
-2,386.63%
Free cash flow per share (TTM)
-4.977
Growth
Earnings per share change (TTM)
-83.35%
3-year earnings per share growth (CAGR)
-74.50%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Calidi Biotherapeutics, Inc. stock?
Calidi Biotherapeutics, Inc. (CLDI) has a market cap of $2.3M as of May 01, 2026.
What is the P/E ratio for Calidi Biotherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Calidi Biotherapeutics, Inc. (CLDI) stock is 0 as of May 01, 2026.
Does Calidi Biotherapeutics, Inc. stock pay dividends?
No, Calidi Biotherapeutics, Inc. (CLDI) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Calidi Biotherapeutics, Inc. dividend payment date?
Calidi Biotherapeutics, Inc. (CLDI) stock does not pay dividends to its shareholders.
What is the beta indicator for Calidi Biotherapeutics, Inc.?
Calidi Biotherapeutics, Inc. (CLDI) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.